199 related articles for article (PubMed ID: 29363546)
1. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
[TBL] [Abstract][Full Text] [Related]
2. [Involvement of innate immunity in the expansion of multiple myeloma cells and therapeutic intervention with lenalidomide].
Furukawa Y; Kuroda Y; Kikuchi J
Rinsho Ketsueki; 2018; 59(8):1048-1057. PubMed ID: 30185705
[TBL] [Abstract][Full Text] [Related]
3. [Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma].
Kikuchi J; Furukawa Y
Rinsho Ketsueki; 2020; 61(7):832-841. PubMed ID: 32759572
[TBL] [Abstract][Full Text] [Related]
4. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
5. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y
Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.
Valcárcel M; Mendoza L; Hernández JJ; Carrascal T; Salado C; Crende O; Vidal-Vanaclocha F
J Transl Med; 2011 Aug; 9():142. PubMed ID: 21867538
[TBL] [Abstract][Full Text] [Related]
7. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
[TBL] [Abstract][Full Text] [Related]
8. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
9. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
10. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy.
Houghton J; Li H; Fan X; Liu Y; Liu JH; Rao VP; Poutahidis T; Taylor CL; Jackson EA; Hewes C; Lyle S; Cerny A; Bowen G; Cerny J; Moore N; Kurt-Jones EA; Erdman SE
Stem Cells Dev; 2010 Aug; 19(8):1153-66. PubMed ID: 20199238
[TBL] [Abstract][Full Text] [Related]
11. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
12. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
13. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
14. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
15. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
16. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide.
Nagai Y; Shimazu R; Ogata H; Akashi S; Sudo K; Yamasaki H; Hayashi S; Iwakura Y; Kimoto M; Miyake K
Blood; 2002 Mar; 99(5):1699-705. PubMed ID: 11861286
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
18. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Tai YT; Acharya C; An G; Moschetta M; Zhong MY; Feng X; Cea M; Cagnetta A; Wen K; van Eenennaam H; van Elsas A; Qiu L; Richardson P; Munshi N; Anderson KC
Blood; 2016 Jun; 127(25):3225-36. PubMed ID: 27127303
[TBL] [Abstract][Full Text] [Related]
19. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
20. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
